166 related articles for article (PubMed ID: 30365949)
21. Characteristics of Helicase-Primase Inhibitor Amenamevir-Resistant Herpes Simplex Virus.
Sato Y; Suenaga T; Kobayashi M; Miyazaki N; Suzuki T; Ishioka K; Suzutani T
Antimicrob Agents Chemother; 2021 Sep; 65(10):e0049421. PubMed ID: 34228537
[TBL] [Abstract][Full Text] [Related]
22. Helicase-primase as a target of new therapies for herpes simplex virus infections.
James SH; Larson KB; Acosta EP; Prichard MN
Clin Pharmacol Ther; 2015 Jan; 97(1):66-78. PubMed ID: 25670384
[TBL] [Abstract][Full Text] [Related]
23. High conservation of varicella-zoster virus helicase-primase complex, the target of the new antiviral drug amenamevir.
Pacreau ML; Bomme O; Burrel S; Boutolleau D
Antiviral Res; 2021 Nov; 195():105189. PubMed ID: 34666108
[TBL] [Abstract][Full Text] [Related]
24. Single amino acid substitutions in the HSV-1 helicase protein that confer resistance to the helicase-primase inhibitor BAY 57-1293 are associated with increased or decreased virus growth characteristics in tissue culture.
Biswas S; Jennens L; Field HJ
Arch Virol; 2007; 152(8):1489-500. PubMed ID: 17404685
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of herpes simplex virus replication by a 2-amino thiazole via interactions with the helicase component of the UL5-UL8-UL52 complex.
Spector FC; Liang L; Giordano H; Sivaraja M; Peterson MG
J Virol; 1998 Sep; 72(9):6979-87. PubMed ID: 9696789
[TBL] [Abstract][Full Text] [Related]
26. Helicase primase: targeting the Achilles heel of herpes simplex viruses.
Kleymann G
Antivir Chem Chemother; 2004 May; 15(3):135-40. PubMed ID: 15266895
[TBL] [Abstract][Full Text] [Related]
27. Statistical analysis of Amenamevir (ASP2151) between pharmacokinetics and clinical efficacies with non-linear effect model for the treatment of genital herpes.
Takada A; Katashima M; Kaibara A; Sawamoto T; Zhang W; Keirns J
Clin Pharmacol Drug Dev; 2014 Sep; 3(5):365-70. PubMed ID: 27129009
[TBL] [Abstract][Full Text] [Related]
28. A single drug-resistance mutation in HSV-1 UL52 primase points to a difference between two helicase-primase inhibitors in their mode of interaction with the antiviral target.
Biswas S; Kleymann G; Swift M; Tiley LS; Lyall J; Aguirre-Hernández J; Field HJ
J Antimicrob Chemother; 2008 May; 61(5):1044-7. PubMed ID: 18299638
[TBL] [Abstract][Full Text] [Related]
29. High frequency of spontaneous helicase-primase inhibitor (BAY 57-1293) drug-resistant variants in certain laboratory isolates of HSV-1.
Biswas S; Swift M; Field HJ
Antivir Chem Chemother; 2007; 18(1):13-23. PubMed ID: 17354648
[TBL] [Abstract][Full Text] [Related]
30. Inhibitory effect of amenamevir on acute herpetic pain and postherpetic neuralgia in mice infected with herpes simplex virus-1.
Ueda Y; Uta D; Tanbo S; Kawabata A; Kanayama S; Osaki M; Nozawa N; Matsumoto T; Andoh T
J Dermatol Sci; 2020 Apr; 98(1):50-57. PubMed ID: 32284168
[TBL] [Abstract][Full Text] [Related]
31. Emergence of varicella-zoster virus resistance to acyclovir: epidemiology, prevention, and treatment.
Shiraki K; Takemoto M; Daikoku T
Expert Rev Anti Infect Ther; 2021 Nov; 19(11):1415-1425. PubMed ID: 33853490
[No Abstract] [Full Text] [Related]
32. Isolation and characterization of herpes simplex virus type 1 resistant to aminothiazolylphenyl-based inhibitors of the viral helicase-primase.
Liuzzi M; Kibler P; Bousquet C; Harji F; Bolger G; Garneau M; Lapeyre N; McCollum RS; Faucher AM; Simoneau B; Cordingley MG
Antiviral Res; 2004 Dec; 64(3):161-70. PubMed ID: 15550269
[TBL] [Abstract][Full Text] [Related]
33. Oral bioavailability and in vivo efficacy of the helicase-primase inhibitor BILS 45 BS against acyclovir-resistant herpes simplex virus type 1.
Duan J; Liuzzi M; Paris W; Liard F; Browne A; Dansereau N; Simoneau B; Faucher AM; Cordingley MG
Antimicrob Agents Chemother; 2003 Jun; 47(6):1798-804. PubMed ID: 12760851
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of a helicase-primase inhibitor in animal models of ocular herpes simplex virus type 1 infection.
Kaufman HE; Varnell ED; Gebhardt BM; Thompson HW; Atwal E; Rübsamen-Waigmann H; Kleymann G
J Ocul Pharmacol Ther; 2008 Feb; 24(1):34-42. PubMed ID: 18201137
[TBL] [Abstract][Full Text] [Related]
35. Effects of therapy using a helicase-primase inhibitor (HPI) in mice infected with deliberate mixtures of wild-type HSV-1 and an HPI-resistant UL5 mutant.
Sukla S; Biswas S; Birkmann A; Lischka P; Ruebsamen-Schaeff H; Zimmermann H; Field HJ
Antiviral Res; 2010 Jul; 87(1):67-73. PubMed ID: 20420855
[TBL] [Abstract][Full Text] [Related]
36. Helicase-primase inhibitors from Medshine Discovery Inc. (WO2018/127207 and WO2020/007355) for the treatment of herpes simplex virus infections - structure proposal for Phaeno Therapeutics drug candidate HN0037.
Gege C; Kleymann G
Expert Opin Ther Pat; 2022 Sep; 32(9):933-937. PubMed ID: 35965439
[TBL] [Abstract][Full Text] [Related]
37. Acyclovir, cidofovir, and amenamevir have additive antiviral effects on herpes simplex virus TYPE 1.
Greeley ZW; Giannasca NJ; Porter MJ; Margulies BJ
Antiviral Res; 2020 Apr; 176():104754. PubMed ID: 32114034
[TBL] [Abstract][Full Text] [Related]
38. The helicase-primase inhibitor BAY 57-1293 reduces the Alzheimer's disease-related molecules induced by herpes simplex virus type 1.
Wozniak MA; Frost AL; Itzhaki RF
Antiviral Res; 2013 Sep; 99(3):401-4. PubMed ID: 23867133
[TBL] [Abstract][Full Text] [Related]
39. [Pharmacological profiles and clinical effects of amenamevir tablet as treatments for herpes zoster].
Maeda H; Nakamura H; Kikukawa Y
Nihon Yakurigaku Zasshi; 2019; 153(1):35-43. PubMed ID: 30643090
[TBL] [Abstract][Full Text] [Related]
40. Antiviral Drugs Against Alphaherpesvirus.
Shiraki K
Adv Exp Med Biol; 2018; 1045():103-122. PubMed ID: 29896665
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
